Placebo + Placebo + RG1507 + RG1507 + erlotinib [Tarceva]
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Squamous Non-Small Cell Lung Cancer
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Trial Timeline
Nov 10, 2008 → Jun 25, 2010
NCT ID
NCT00760929About Placebo + Placebo + RG1507 + RG1507 + erlotinib [Tarceva]
Placebo + Placebo + RG1507 + RG1507 + erlotinib [Tarceva] is a phase 2 stage product being developed by Roche for Non-Squamous Non-Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00760929. Target conditions include Non-Squamous Non-Small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-Squamous Non-Small Cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00760929 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-Squamous Non-Small Cell Lung Cancer